Resumen
Background: Bevacizumab belongs to a group of monoclonal antibodies that act by binding to all isoforms
of vascular endothelial growth factors (VEGF) thus preventing the activation of effector pathways that lead
to formation of new and unstable blood vessels in the retina. It has been used off-label for the treatment of
proliferative pathologies of the retina, with promising results. Objective: To determine the effect of a 3 doses
administration of intravitreous bevacizumab on central macular thickness measured by optical coherence
tomography (OCT) 1 month after the last injection and also to establish a database of the epidemiologic
characteristics of the patients and their response to treatment with intravitreous bevacizumab. Method: This
is a quasi-experimental retrospective design of before and after an intervention. A population of 261 cases
reviewed to obtain general data of each patient as well as the central macular thickness measured by OCT
before and 1 month after treatment with intravitreous bevacizumab. Results were then compared using
Student’s T test for the difference of two means. Results: A reduction of 19% (p < 0.0001) in central macular
thickness measured by OCT was observed in the overall population of the study. These results did not apply
to all patients when classified by indication of treatment (base pathology). Conclusion: Results suggest that
a 3 dose treatment of intravitreous bevacizumab is effective in the reduction of mean central macular
thickness measured by OCT 1 month after intervention.
Citas
Yang CS, Hung KC, Huang YM, et al. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2013; 29(6): 550–555.
Michels S, Collet L, Larson TA, et al. Bevacizumab for ophthalmic diseases. USExpert Review of Ophthalmology 2007; 2(3): 369–378.
Arévalo J, García-Amaris R. Intravitreal Bevacizumab for Diabetic Retinopathy. Current Diabetes Reviews 2009; 5(1): 39-46.
Huang D, et al. Optical coherence tomography. Science 1991; 254 (5035): 1178–1181.
Avery RL, Pieramici DJ, Rabena MD. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363–372.
Haritoglou C, Kook D, Neubauer A, et al., Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999–1005.
Avery RL, Pieramici DJ, Rabena MD. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363–372. 8.Haritoglou C, Kook D, Neubauer A, et al., Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006; 26: 999–1005
Copyright
License
Copyright (c) 2017 Martin Barrios Fernández, Jose Manuel del Cid
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License 4.0 (CC BY-NC_SA 4.0) that indicates: a) It is allowed that others share the work, with an acknowledgement of the work's authorship and initial publication in this journal, b) The work may not be used for commercial purposes, c) If it's remixed, transformed, or built upon the material, one must distribute the contributions under the same license as the original
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository, website or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
© 2017 Martin Barrios Fernández, Jose Manuel del Cid
